GeneHealth - Your precision medicine

Osteopetrosis

Disease Details

Family Health Simplified

Buy Membership

Description: Osteopetrosis, also known as marble bone disease, is a genetic disorder characterized by the abnormal hardening and densification of bones due to defective osteoclast function, leading to brittle bones and a range of associated complications.
Type: Osteopetrosis can be inherited in more than one way. It primarily presents in two forms with different modes of genetic transmission:

1. **Autosomal Recessive Osteopetrosis (ARO)**: This is the more severe form, usually evident in infancy or early childhood. Both parents must carry one copy of the mutated gene to pass the condition on to their child.

2. **Autosomal Dominant Osteopetrosis (ADO)**: This is typically the milder form, often diagnosed in adolescence or adulthood. Only one copy of the mutated gene from either parent can cause the disorder.

There are also rarer instances where osteopetrosis can be X-linked, but these cases are less common.
Signs And Symptoms: Despite this excess bone formation, people with osteopetrosis tend to have bones that are more brittle than normal. Mild osteopetrosis may cause no symptoms, and present no problems.
However, serious forms can result in the following:
Stunted growth, deformity, and increased likelihood of fractures
Patients experience anemia, recurrent infections, and hepatosplenomegaly due to bone expansion leading to bone marrow narrowing and extramedullary hematopoiesis
It can also result in blindness, facial paralysis, and deafness, due to the increased pressure put on the nerves by the extra bone
Abnormal cortical bone morphology
Abnormal form of the vertebral bodies
Abnormality of temperature regulation
Abnormality of the ribs
Abnormality of vertebral epiphysis morphology
Bone pain
Cranial nerve paralysis
Craniosynostosis
Hearing impairment
Hypocalcemia
Prognosis: The long-term-outlook for people with osteopetrosis depends on the subtype and the severity of the condition in each person. The severe infantile forms of osteopetrosis are associated with shortened life expectancy, with most untreated children not surviving past their first decade. Bone marrow transplantation seems to have cured some infants with early-onset disease. However, the long-term prognosis after transplantation is unknown. For those with onset in childhood or adolescence, the effect of the condition depends on the specific symptoms (including how fragile the bones are and how much pain is present). Life expectancy in the adult-onset forms is normal.
Onset: Osteopetrosis, also known as marble bone disease, typically presents in infancy or early childhood. However, there are milder forms that may not be diagnosed until adolescence or adulthood. The neonatal form is the most severe and can be apparent at birth or shortly thereafter.
Prevalence: Osteopetrosis is a rare genetic disorder. Its prevalence is estimated to be approximately 1 in 20,000 to 1 in 250,000 individuals, depending on the specific type and geographic location.
Epidemiology: Osteopetrosis is a rare genetic disorder characterized by the abnormal hardening and density of bones. It occurs with an estimated incidence of 1 in 100,000 to 500,000 births. There are several forms of the disease, with autosomal recessive types typically presenting more severely and earlier in life, whereas autosomal dominant types generally have a milder adult onset.
Intractability: Osteopetrosis is generally considered intractable, meaning it is difficult to treat or manage effectively. While there are treatments that can alleviate symptoms and improve quality of life, such as bone marrow transplants, these options do not cure the disease and their effectiveness can vary.
Disease Severity: Osteopetrosis disease_severity: Osteopetrosis, also known as "marble bone disease," varies in severity. It exists in several forms, including autosomal recessive (infantile), autosomal dominant (adult), and intermediate forms. Infantile osteopetrosis is typically severe and can be life-threatening, often presenting in infancy with symptoms like bone fractures, anemia, and nerve compression. The adult form is generally milder, presenting later in life with a higher risk of fractures and other skeletal issues. Intermediate forms show a spectrum of severity between these two extremes.
Healthcare Professionals: Disease Ontology ID - DOID:13533
Pathophysiology: Osteopetrosis, also known as marble bone disease, is characterized by defective osteoclast-mediated bone resorption. Normally, osteoclasts break down bone tissue to regulate bone remodeling and calcium levels. In osteopetrosis, genetic mutations impair the function or development of osteoclasts, leading to the accumulation of abnormally dense bone. This results in brittle bones prone to fractures, bone marrow failure due to the encroachment of bone on the marrow cavities, and other complications such as cranial nerve compression and osteomyelitis.
Carrier Status: Osteopetrosis is typically inherited in an autosomal recessive or autosomal dominant pattern, depending on the specific type. Carrier status usually applies to the autosomal recessive forms, where an individual with one defective copy of the responsible gene and one normal copy is considered a carrier. Carriers generally do not exhibit symptoms of the disease. For autosomal dominant forms, carriers may show symptoms due to the nature of the inheritance pattern.
Mechanism: Osteopetrosis, also known as marble bone disease, is a rare inherited disorder characterized by the abnormal hardening and densification of bone.

**Mechanism:**
The primary mechanism of osteopetrosis involves defective osteoclasts, which are the cells responsible for bone resorption. This defect leads to an imbalance between bone formation by osteoblasts and bone resorption, resulting in the abnormal accumulation of dense, brittle bone.

**Molecular Mechanisms:**
1. **Gene Mutations:** Several genes have been implicated in osteopetrosis, including:
- **TCIRG1:** Mutations in this gene, which encodes a subunit of the vacuolar H+-ATPase proton pump, are the most common cause of autosomal recessive osteopetrosis. The proton pump is crucial for acidifying the resorption lacuna, an essential step in bone resorption.
- **CLCN7:** This gene encodes a chloride channel protein important for the osteoclast’s acidification process. Mutations can lead to both autosomal dominant and recessive forms of the disease.
- **OSTM1:** Mutations in this gene affect a protein involved in osteoclast function and can lead to severe autosomal recessive osteopetrosis.

2. **Osteoclast Dysfunction:** The affected genes typically result in dysfunctional or deficient osteoclasts, leading to impaired bone resorption. This may involve insufficient acidification of the resorption zone, reduced chloride transport, or other cellular malfunctions that inhibit the osteoclasts' ability to break down bone tissue effectively.

3. **Bone Remodeling Imbalance:** Due to defective osteoclasts, the normal balance of bone remodeling is disrupted. Osteoblasts continue to form bone, but the lack of adequate bone resorption by osteoclasts leads to increased bone density, brittleness, and various clinical complications such as fractures, bone marrow failure, and nerve compression.

Understanding these mechanisms is key to developing targeted therapies and managing the symptoms of osteopetrosis effectively.
Treatment: It was the first genetic disease treated with hematopoietic stem cell transplantation (osteoclasts are derived from hematopoietic precursors). There is no cure, although curative therapy with bone marrow transplantion is being investigated in clinical trials. It is believed the healthy marrow will provide cells from which osteoclasts will develop. If complications occur in children, patients can be treated with vitamin D. Gamma interferon has also been shown to be effective, and it can be associated to vitamin D. Erythropoetin has been used to treat any associated anemia. Corticosteroids may alleviate both the anemia and stimulate bone resorption. Fractures and osteomyelitis can be treated as usual. Treatment for osteopetrosis depends on the specific symptoms present and the severity in each person. Therefore, treatment options must be evaluated on an individual basis. Nutritional support is important to improve growth and it also enhances responsiveness to other treatment options. A calcium-deficient diet has been beneficial for some affected people.Treatment is necessary for the infantile form:
Vitamin D (calcitriol) appears to stimulate dormant osteoclasts, which stimulates bone resorption
Gamma interferon can have long-term benefits. It improves white blood cell function (leading to fewer infections), decreases bone volume, and increases bone marrow volume.
Erythropoietin can be used for anemia, and corticosteroids can be used for anemia and to stimulate bone resorption.Bone marrow transplantation (BMT) improves some cases of severe, infantile osteopetrosis associated with bone marrow failure, and offers the best chance of longer-term survival for individuals with this type.In pediatric (childhood) osteopetrosis, surgery is sometimes needed because of fractures. Adult osteopetrosis typically does not require treatment, but complications of the condition may require intervention. Surgery may be needed for aesthetic or functional reasons (such as multiple fractures, deformity, and loss of function), or for severe degenerative joint disease.
Compassionate Use Treatment: In the context of osteopetrosis, compassionate use treatment typically involves experimental or off-label therapies in severe cases where conventional treatments have failed or are not available. This might include:

1. **Bone Marrow Transplantation (BMT)**: This is currently considered the only definitive treatment for certain severe forms of osteopetrosis, particularly for infants with malignant infantile osteopetrosis. BMT can restore normal bone resorption by providing the patient with healthy osteoclasts from the donor.

2. **Interferon-gamma (IFN-γ)**: This has been used off-label in some cases to improve bone resorption and reduce the risk of fractures and other complications.

3. **Prednisone**: This corticosteroid is sometimes used off-label to stimulate bone resorption and improve some symptoms.

4. **Parathyroid Hormone (PTH) Therapy**: Experimental use of PTH has been considered to help enhance bone resorption in certain patients.

5. **Genetic Therapies**: Research is ongoing into gene therapy and other targeted treatments that can address the underlying genetic defects in osteopetrosis.

These treatments are generally considered when the disease is severe, and the potential benefits outweigh the risks. Decisions are usually made on a case-by-case basis in consultation with specialists.
Lifestyle Recommendations: For individuals with osteopetrosis, lifestyle recommendations may include:

1. **Regular Monitoring**: Frequent check-ups with healthcare providers to monitor the progression of the disease and assess bone health.
2. **Bone Health**: Intake of a well-balanced diet rich in calcium and vitamin D to support bone health, as advised by a healthcare provider.
3. **Physical Activity**: Engage in low-impact exercises such as swimming or walking to maintain overall health and avoid high-risk activities that might cause fractures.
4. **Infection Prevention**: Maintain good oral hygiene and regular dental check-ups to prevent dental infections, which can be common in osteopetrosis.
5. **Medication Adherence**: Follow any prescribed treatment plans, which may include medications to manage symptoms or underlying causes as directed by a healthcare professional.
6. **Fall Prevention**: Implement home safety modifications to prevent falls, such as installing grab bars and ensuring adequate lighting.

It is essential to work closely with healthcare professionals to tailor these recommendations to the individual’s specific condition and needs.
Medication: Osteopetrosis, also known as marble bone disease, is a rare genetic disorder characterized by the abnormal hardening of bones. Treatment often depends on the severity of the disease:

1. **Interferon-gamma-1b (Actimmune):** Can be used to stimulate the immune system and improve bone resorption.
2. **Bone Marrow Transplantation:** Considered the best option for patients with severe forms, as it can provide a source of normal osteoclasts.
3. **Calcitriol:** May be used to stimulate bone resorption.
4. **Hematopoietic Stem Cell Transplantation (HSCT):** Another effective treatment for severe forms, especially in infants and young children.

Supportive treatments include physical therapy and medications to manage symptoms and complications such as fractures and anemia.
Repurposable Drugs: Osteopetrosis is a rare inherited disorder characterized by the abnormal hardening of bone. Limited information is available on repurposable drugs specifically for this condition, but bone marrow transplants and certain medications like interferon gamma-1b have been explored. Further research is needed to identify more repurposable drugs.
Metabolites: Osteopetrosis, also known as marble bone disease, is a rare genetic disorder characterized by the abnormal hardening and increased density of bones. This condition results from dysfunctional osteoclasts, which are responsible for bone resorption.

Regarding metabolites, osteopetrosis does not have specific metabolites directly associated with the disease itself. However, metabolic abnormalities may occur secondary to the disease’s impact on bone marrow function, potentially leading to issues such as:

- Hypocalcemia (low calcium levels)
- Hypercalcemia (high calcium levels) in some cases when bone resorption occasionally releases calcium
- Anemia, due to impaired hematopoiesis in the bone marrow
- Low levels of parathyroid hormone (PTH), potentially secondary to hypocalcemia

These abnormalities in metabolic parameters reflect the broader systemic impact of osteopetrosis rather than being specific metabolites of the disease itself.
Nutraceuticals: For osteopetrosis, there is currently no established nutraceutical treatment. Management typically focuses on medical treatments like bone marrow transplantation, and supportive care. It is important to consult with healthcare providers for appropriate diagnosis and treatment options.
Peptides: For osteopetrosis, research into peptides and nanotechnology is still in exploratory phases. Peptides can potentially be used to target and modulate specific pathways involved in bone resorption and formation. Nanotechnology offers avenues for drug delivery systems that enhance the targeting and effectiveness of treatments. Current efforts are largely experimental, focusing on improving therapy efficacy and reducing side effects.